Skip to main content

ibsrela

Generic: TENAPANOR HYDROCHLORIDE

ibsrela: developed by 1 company · 1 FDA decision.

ibsrela evidence translation

What we can confirm

What it means

Source-backed records connect ibsrela to ARDX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could ibsrela → ARDX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Irritable bowel syndrome with constipation (IBS-C) in adults

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
ARDELYX, INC. (ARDX)
Irritable bowel syndrome with constipation (IBS-C) in adults
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. ( 1 )(ARDX)FDA ↗
NDA211801Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Who is developing ibsrela?

ibsrela is being developed by ARDELYX, INC..

What is ibsrela's latest FDA decision?

The most recent tracked FDA decision for ibsrela is Approval for 1 INDICATIONS AND USAGE IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. ( 1 ), dated September 12, 2019.